Limited cognitive enhancement over 3 months for 9 patients? What exactly does she mean by "limited cog enhancements" and where are those results? Where's the beef? And from that Suzanne thinks this current batch of patients will perform much better? Why? Most Alzheimers trials show cognitive enhancement in the short term. Seems presumptuous to insinuate/suggest reversal based on limited cog improvement in just 9 patients over just 3 months.
Minute 8:25 "we are seeing remarkable results in reversal of Alzheimer's Disease"
Minute 10:41 "with this license we are able to synthesize Bryostatin in larger commercial quantities"
Minute 17:58 "we have compassionate use protocol results in Alzheimer patients that shows significant improvement in cognition and daily living..."
Minute 18:25: “we have Phase 2a completed which was a smaller Phase 2. We achieved our primary safety endpoint, we saw targeted engagement and we saw some limited cognitive enhancement in a short period of time.
Minute 26:42: “we are testing in late stage patients to make the point of a significant reversal (in AD). This treatment should be applicable to moderate to early stage to MCI (mild cognitive impairment) patients.
News 
Market Data 
Discover 
